Change in the total number of shares and votes in Recipharm AB (publ)
As of 30 June 2020, the total number of shares in Recipharm AB (publ) (“Recipharm”) amounts to 100,990,187 shares, divided into 21,311,998 shares of series A and 79,678,189 shares of series B. The total number of votes in Recipharm as of 30 June 2020 amounts to 292,798,169.
The number of shares and votes in Recipharm has increased as a result of the registration of 6,089,140 shares of series A and 22 600 368 shares of series B subscribed for by the exercise of subscription rights in the ongoing rights issue in Recipharm, which was resolved on May 26, 2020.
For more information please visit www.recipharm.com or contact:
Thomas Eldered, CEO, ir@recipharm.com, telephone: +46 8 602 52 10
This information is published in accordance with Chapter 4, Section 9 of the Swedish Financial Instruments Trading Act (SFS 1991:980). This information was submitted for publication on 30 June 2020, at 08:00 am CEST.
About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s annual turnover is approximately SEK 11 billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com
Recipharm AB (publ)
Corporate identity number 556498-8425
Address Box 603, SE-101 32 Stockholm, Sweden, Telephone +46 8 602 52 00
www.recipharm.com
Tags: